SCHEMBL6684488

SCHEMBL6684488

CCC1OC(=O)N(Cc2cccc(NC(=O)c3ccncc3)c2)N=C1c1ccc(OC)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 11/20 0.45
PDE4A P27815 10/20 0.45
PDE4B Q07343 10/20 0.45
PDE4C Q08493 10/20 0.45
LMNA P02545 3/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ACKR3 P25106 2/20 0.42
MET P08581 1/20 0.42
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
NAMPT P43490 1/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL146252 0.92 PDE4A (0.46) PDE4DPDE4APDE4BPDE4CLMNA
SCHEMBL6686026 0.92 PDE4A (0.49) PDE4DPDE4APDE4BPDE4CACKR3
SCHEMBL6689118 0.91 LMNA (0.51) PDE4DPDE4APDE4BPDE4CLMNA
SCHEMBL6656438 0.90 PDE4D (0.44) PDE4DPDE4APDE4BPDE4CSMN1; SMN2
SCHEMBL6653521 0.89 ACKR3 (0.44) PDE4DPDE4APDE4BPDE4CLMNA
SCHEMBL6653612 0.88 KDM4E (0.49) PDE4DPDE4APDE4BPDE4CSMN1; SMN2
SCHEMBL6684977 0.88 PDE4D (0.43) PDE4DPDE4APDE4BPDE4CMAPK1
SCHEMBL6657995 0.88 PDE4D (0.43) PDE4DPDE4APDE4BPDE4CMAPK1
SCHEMBL6654394 0.88 TSHR (0.49) PDE4DPDE4APDE4BPDE4CLMNA
SCHEMBL6657334 0.88 L3MBTL1 (0.49) PDE4DPDE4APDE4BPDE4CLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B PDE4D 12/4885PDE4A 1/4885PDE4B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.